AI Article Synopsis
- Case notes of 202 patients prescribed Optimax L-tryptophan between 1987 and 1991 were reviewed for potential eosinophilia-myalgia syndrome (EMS) diagnoses.
- Fourteen patients showed clinical or lab indicators suggesting EMS; however, further tests negated this diagnosis for all of them.
- A separate study involving 50 patients taking L-tryptophan found only 5 with mild eosinophilia, none meeting the CDC criteria for EMS.
Article Abstract
Case notes of 202 patients who were prescribed a single brand of L-tryptophan (Optimax, manufactured by Merck) between January 1987 and December 1991 were examined. Fourteen patients' notes indicated that they had clinical or laboratory findings suggestive of a diagnosis of eosinophilia-myalgia syndrome (EMS). However, results of clinical examination and measurement of serum aldolase, total eosinophil count and antinuclear antibodies did not support the diagnosis of EMS in any of the 14 patients. Although a further study of 50 consecutive patients on L-tryptophan at the time of the investigation revealed that 5 had mild eosinophilia, none reached the criteria for EMS established by the US Centers for Disease Control and Prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0447.1994.tb01623.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!